VIBRAMYCIN Oral Suspension Gets FDA Safety Seal of Approval
Published Date: 4/9/2025
Notice
Summary
The FDA says VIBRAMYCIN oral suspension (25 mg/5 mL) wasn’t pulled from the market because of safety or effectiveness problems. This means generic versions can keep getting approved, so patients and pharmacies won’t face shortages or price hikes. If you rely on this medicine, good news—it’s here to stay!
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Generic Approvals Continue for VIBRAMYCIN
The FDA determined that VIBRAMYCIN (doxycycline) oral suspension, equivalent 25 mg base/5 mL, was not withdrawn from sale for reasons of safety or effectiveness. Because of that determination, the FDA will not begin procedures to withdraw approvals of abbreviated new drug applications (ANDAs) that refer to this product and can continue to approve ANDAs that refer to it if they meet legal and regulatory requirements.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in